Vascular Biogenics Ltd

NASDAQ:VBLT   2:11:35 PM EDT
2.32
-0.01 (-0.43%)
Products

Vbl Therapeutics Resumes U.S. Enrollment In Oval Phase 3 Trial As FDA Authorizes Clinical Use Of Vb-111 Batches Produced In Modiin Facility

Published: 08/30/2021 11:43 GMT
Vascular Biogenics Ltd (VBLT) - Vbl Therapeutics Resumes U.S. Enrollment in Oval Phase 3 Trial As FDA Authorizes Clinical Use of Vb-111 Batches Produced in Modiin Facility.
Vascular Biogenics - U.S. FDA Cmc Clearance of Vb-111 Produced in Modiin, Israel Facility an Important Milestone Toward Potential Commercialization.
Vascular Biogenics Ltd - Oval Phase 3 Trial Evaluating Vb-111 in Platinum Resistant Ovarian Cancer Has Recruited Nearly 80% of Target Enrollment.
Vascular Biogenics Ltd - Oval Phase 3 Trial Remains on Track to Complete Enrollment in 1q22.
Vascular Biogenics Ltd - Oval Pfs Readout Expected in 2h22 May Support Bla Submission.